Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Revenue Expected to Reach $8.59 Billion by 2030 with 22% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market From 2026 To 2030?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market has experienced significant growth in recent years. It is anticipated to expand from $3.18 billion in 2025 to $3.88 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.2%. The historical growth of this market can be attributed to the increasing prevalence of obesity, a rise in the incidence of type 2 diabetes, greater awareness of liver health disorders, the expansion of diagnostic testing capabilities, and the early adoption of lifestyle modification programs.
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market is projected to experience substantial growth over the coming years. It is expected to expand to $8.6 billion by 2030, achieving a compound annual growth rate (CAGR) of 22.0%. This expansion during the projection period is primarily driven by factors such as the growing adoption of GLP-1 agonists, advancements in antifibrotic drug development, increased use of digital liver monitoring tools, broader application of bariatric surgery, and a heightened emphasis on personalized metabolic therapies. Key trends anticipated during this period encompass the development of precision therapeutics for liver diseases, the integration of AI-enabled early detection and risk stratification, cloud-based solutions for liver health data management, IoT-integrated systems for lifestyle and medication monitoring, and an increase in sustainable and preventive metabolic health initiatives.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
What Drivers Are Influencing The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The rising occurrence of obesity is anticipated to drive the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in the future. Obesity is defined as a medical state where excessive body fat accumulates, potentially harming general health, and is usually identified by a body mass index (BMI) of 30 or greater. Globally, obesity rates are climbing, fueled by inactive lifestyles, poor dietary habits, and various metabolic risk factors. For individuals with obesity, treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH) aims to tackle insulin resistance, decrease liver fat, and enhance metabolic well-being through modifications in lifestyle and specific therapeutic interventions. As an illustration, the World Heart Foundation, a global cardiovascular community based in Switzerland, reported in March 2023 that around 2.3 billion adults and children globally are currently obese or overweight, with projections indicating this figure will grow to 2.7 billion by 2025 due to continuing obesity trends. Consequently, the escalating rates of obesity are fueling the expansion within the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
Which Segments Are Included In The Analysis Of The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The metabolic dysfunction-associated steatohepatitis (mash) treatment market covered in this report is segmented –
1) By Treatment: Drug, Therapy
2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
What Industry Trends Are Redefining The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Major companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are concentrating on developing innovative products, such as liver fibrosis treatment solutions, to offer therapeutic options for patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. These liver fibrosis treatment solutions are designed to address the fundamental causes of liver damage through lifestyle adjustments, antiviral medications, and emerging antifibrotic therapies, with the objective of halting or reversing fibrosis progression and enhancing liver function. For instance, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom), which is the first-ever treatment specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily oral tablet that demonstrated its efficacy in resolving MASH without exacerbating fibrosis and improved liver fibrosis in phase 3 clinical trials. This advancement provides a non-invasive treatment option, eliminating the requirement for liver biopsies, and significantly boosts patient access and outcomes in managing fatty liver disease.
Which Key Industry Participants Are Active In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA
Read the full metabolic dysfunction-associated steatohepatitis (mash) treatment market report here:
Which Regions Are Expected To Experience Rapid Expansion In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (mash) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp
Browse Through More Reports Similar to the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market 2026, By The Business Research Company
Renal Biomarkers Global Market Report
https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report
Cancer Biomarker Global Market Report
https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report
Non Alcoholic Steatohepatitis Biomarkers Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
